223 DAYS. 0 ATTACKS.^* THE RIGHT THERAPY MATTERS

HAEGARDA is the HAE therapy that reduced attacks by 95%^†

* In a post-hoc analysis of 63 patients, median time to first attack in patients followed over 1.5 years in a long-term, open-label study was 224 days.¹

^† In the pivotal trial, median reduction in the number of attacks in people receiving HAEGARDA 60 IU/kg vs placebo.

HAEGARDA is the only HAE preventive therapy that delivers:

arrow pointing downwards with 95 percent symbol

95% reduction in HAE attacks

arrow pointing downwards with 99 percent symbol

>99% less rescue medication use

Replacing missing or dysfunctional C1-INH

MORE ABOUT EFFICACY

LEARN MORE

WAO Guideline for the Management of HAE states that patients should have HAE rescue medication available at all times.³

^‡Median reduction in number of attacks in patients receiving 60 IU/kg of HAEGARDA vs placebo.

^§Median reduction in rescue medication use with HAEGARDA 60 IU/kg vs placebo.

Get your patients started on HAEGARDA

PRESCRIBING HAEGARDA

REFERENCES: 1. Craig T, Feuersenger H, Pragst I. Durability of symptom control with long-term prophylactic therapy with subcutaneous C1-inhibitor in patients with hereditary angioedema. Presented at the 33rd Annual Eastern Allergy Conference. Palm Beach, FL. August 16-18, 2020. 2. Longhurst H, Cicardi M, Craig T, et al. Prevention of hereditary angioedema attacks with a subcutaneous C1 inhibitor. N Engl J Med. 2017;376(12):1131-1140. 3. Maurer M, Magerl M, Ansotegui I, et al. The international WAO/EEACI guideline for the management of hereditary angioedema—the 2017 revision and update. Allergy. 2018;73(8):1575-1596.

Have additional questions?

Connect with CSL Behring Medical Affairs to find additional information and ask questions.

Visit medical affairs

223 DAYS. 0 ATTACKS.* THE RIGHT THERAPY MATTERS